Who We Are

Leveraging deep expertise in biologic development from discovery to IND-enabling studies (CMC & TOX), our team is developing a unique immunotherapy to combat the devastating consequence of cancer metastasis.

Metastasis is responsible for the overwhelming majority of cancer deaths. Despite decades of research with enormous investment, blocking or reversing cancer progression to metastasis remains a formidable challenge.

Our distinctive technology is designed to compel immunogenic changes within TME, convert a tumor mass into potent immunogens, leading to antitumor immunity to distant, untreated tumors & achieving therapeutic effects.